Theoretically, to increase efficiency of PARP1 inhibitors in cancer therapy, we could modulate the activity of proteins related to its function; this could enhance clinical utility of PARP inhibitors and give further clue to address the resistance to PARP inhibitors. This evidence concerns the gene PARP1 and cancer.